Cargando…

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

Therapies that produce deep and durable responses in patients with metastatic melanoma are needed. This phase II cohort from the international, single-arm PIVOT-02 study evaluated the CD122-preferential interleukin-2 pathway agonist bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in first-line meta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Diab, Adi, Tykodi, Scott S., Daniels, Gregory A., Maio, Michele, Curti, Brendan D., Lewis, Karl D., Jang, Sekwon, Kalinka, Ewa, Puzanov, Igor, Spira, Alexander I., Cho, Daniel C., Guan, Shanhong, Puente, Erika, Nguyen, Tuan, Hoch, Ute, Currie, Sue L., Lin, Wei, Tagliaferri, Mary A., Zalevsky, Jonathan, Sznol, Mario, Hurwitz, Michael E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2021
Materias:	Original Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425826/ https://www.ncbi.nlm.nih.gov/pubmed/34255535 http://dx.doi.org/10.1200/JCO.21.00675

Ejemplares similares

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
por: Tannir, Nizar M, et al.
Publicado: (2022)

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results
por: Diab, Adi, et al.
Publicado: (2023)

Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab
por: Veatch, Joshua R, et al.
Publicado: (2020)

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
por: Sharma, Meenu, et al.
Publicado: (2020)

Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
por: D’Angelo, Sandra P., et al.
Publicado: (2022)

Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report
por: Anastasopoulou, Amalia, et al.
Publicado: (2022)

Bempegaldesleukin (BEMPEG; NKTR‐214) efficacy as a single agent and in combination with checkpoint‐inhibitor therapy in mouse models of osteosarcoma
por: Hennessy, Marlene, et al.
Publicado: (2020)

Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice
por: Pieper, Alexander A, et al.
Publicado: (2021)

Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
por: Sznol, Mario, et al.
Publicado: (2015)

Combination of Bempegaldesleukin and Anti-CTLA-4 Prevents Metastatic Dissemination After Primary Resection or Radiotherapy in a Preclinical Model of Non-Small Cell Lung Cancer
por: Bates, Amber M., et al.
Publicado: (2021)

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
por: Ross-Macdonald, Petra, et al.
Publicado: (2021)

Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial
por: Feils, A. S., et al.
Publicado: (2023)

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
por: Tawbi, Hussein A, et al.
Publicado: (2021)

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
por: Long, Georgina V, et al.
Publicado: (2015)

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer
por: Long, G V, et al.
Publicado: (2018)

Pre-treatment patient selection for nivolumab benefit based on serum mass spectra
por: Weber, Jeffrey, et al.
Publicado: (2015)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial
por: George, Daniel J, et al.
Publicado: (2022)

Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8(+) T cell cytotoxicity over BEMPEG+RT
por: Rolig, Annah S, et al.
Publicado: (2022)

Neoadjuvant relatlimab and nivolumab in resectable melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2022)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2022)

Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report
por: Sadaat, Masood, et al.
Publicado: (2018)

Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2023)

Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)
por: Hodi, F. Stephen, et al.
Publicado: (2020)

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
por: Choueiri, Toni K, et al.
Publicado: (2022)

PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence
por: Tykodi, Scott S
Publicado: (2014)

Into the Clinic With Nivolumab and Pembrolizumab
por: Shu, Catherine A., et al.
Publicado: (2016)

Focus on Nivolumab in NSCLC
por: Cortinovis, Diego L., et al.
Publicado: (2016)

Nivolumab‐induced sialadenitis
por: Takahashi, Saeko, et al.
Publicado: (2018)

Nivolumab – Pearls of Evidence
por: Chaudhari, Pratishtha B
Publicado: (2017)

A case of nivolumab-induced scleroderma-like syndrome successfully treated with intravenous immunoglobulin
por: DeMaio, Alexa, et al.
Publicado: (2022)

Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review
por: McDonald, Marin A., et al.
Publicado: (2018)

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920
por: Emamekhoo, Hamid, et al.
Publicado: (2021)

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
por: Robert, Caroline, et al.
Publicado: (2020)

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
por: Najjar, Yana G, et al.
Publicado: (2020)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

A taste of science
por: Tykodi, Ralph J
Publicado: (1975)

Antiphospholipid Antibody Induced by Nivolumab
por: Aburahma, Ahmed, et al.
Publicado: (2018)

Nivolumab-induced systemic vasculitis
por: Kang, Alison, et al.
Publicado: (2018)

Nivolumab induced myxedema crisis
por: Khan, Uqba, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fkmva5k3dehn4n4ng2aq0dgsnb